{"title":"修正“在临床实践中将人群药代动力学建模与精确给药相结合的推荐方法”。","authors":"","doi":"10.1002/bcp.70106","DOIUrl":null,"url":null,"abstract":"<p>\n <span>Berezowska, M</span>, <span>Hayden, IS</span>, <span>Brandon, AM</span>, et al. <span>Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice</span>. <i>Br J Clin Pharmacol</i>. <span>2025</span>; <span>91</span>(<span>4</span>): <span>1064</span>-<span>1079</span>. 10.1111/bcp.16335</p><p>In Section 7 (“Outlook for MIPD”), the citation to reference 115 in the phrase “hybridising NLME and ML models to improve upon MAP parameter estimates” was incorrect. This should have referred to a different publication authored by the same group.</p><p>The corrected sentence should read:</p><p>“Several proof-of-concept works have successfully demonstrated replacing popPK models with ML models for PK parameter prediction [143], hybridising NLME and ML models to improve upon MAP parameter estimates [new reference], using ML algorithms to accelerate NLME model development [144] and creating more realistic synthetic PK data by use of ML [145].”</p><p>The newly cited reference is:</p><p>Hughes JH, Keizer RJ. A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors. CPT Pharmacometrics Syst Pharmacol. 2021; 10: 1150–1160. https://doi.org/10.1002/psp4.12684</p><p>We apologize for this error.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":"91 7","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bcp.70106","citationCount":"0","resultStr":"{\"title\":\"Correction to “Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice”\",\"authors\":\"\",\"doi\":\"10.1002/bcp.70106\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>\\n <span>Berezowska, M</span>, <span>Hayden, IS</span>, <span>Brandon, AM</span>, et al. <span>Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice</span>. <i>Br J Clin Pharmacol</i>. <span>2025</span>; <span>91</span>(<span>4</span>): <span>1064</span>-<span>1079</span>. 10.1111/bcp.16335</p><p>In Section 7 (“Outlook for MIPD”), the citation to reference 115 in the phrase “hybridising NLME and ML models to improve upon MAP parameter estimates” was incorrect. This should have referred to a different publication authored by the same group.</p><p>The corrected sentence should read:</p><p>“Several proof-of-concept works have successfully demonstrated replacing popPK models with ML models for PK parameter prediction [143], hybridising NLME and ML models to improve upon MAP parameter estimates [new reference], using ML algorithms to accelerate NLME model development [144] and creating more realistic synthetic PK data by use of ML [145].”</p><p>The newly cited reference is:</p><p>Hughes JH, Keizer RJ. A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors. CPT Pharmacometrics Syst Pharmacol. 2021; 10: 1150–1160. https://doi.org/10.1002/psp4.12684</p><p>We apologize for this error.</p>\",\"PeriodicalId\":9251,\"journal\":{\"name\":\"British journal of clinical pharmacology\",\"volume\":\"91 7\",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-05-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bcp.70106\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British journal of clinical pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/bcp.70106\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of clinical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/bcp.70106","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Correction to “Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice”
Berezowska, M, Hayden, IS, Brandon, AM, et al. Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice. Br J Clin Pharmacol. 2025; 91(4): 1064-1079. 10.1111/bcp.16335
In Section 7 (“Outlook for MIPD”), the citation to reference 115 in the phrase “hybridising NLME and ML models to improve upon MAP parameter estimates” was incorrect. This should have referred to a different publication authored by the same group.
The corrected sentence should read:
“Several proof-of-concept works have successfully demonstrated replacing popPK models with ML models for PK parameter prediction [143], hybridising NLME and ML models to improve upon MAP parameter estimates [new reference], using ML algorithms to accelerate NLME model development [144] and creating more realistic synthetic PK data by use of ML [145].”
The newly cited reference is:
Hughes JH, Keizer RJ. A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors. CPT Pharmacometrics Syst Pharmacol. 2021; 10: 1150–1160. https://doi.org/10.1002/psp4.12684
期刊介绍:
Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.